Potential involvement of type II phospholipase A2 in atherosclerosis.
Hurt-Camejo
E
E
Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg, Sweden. Eva.Hurt@wlab.wall.gu.se
Camejo
G
G
D001161:Arteriosclerosis / Q000201:enzymology* / Q000473:pathology; D015777:Eicosanoids / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D054501:Group II Phospholipases A2; D006801:Humans; D006868:Hydrolysis; D007249:Inflammation; D007371:Interferon-gamma / Q000502:physiology; D008077:Lipoproteins, LDL / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000378:metabolism; D008954:Models, Biological; D009131:Muscle, Smooth, Vascular / Q000201:enzymology* / Q000473:pathology; D010741:Phospholipases A / Q000502:physiology*; D054467:Phospholipases A2; D015290:Second Messenger Systems
D015777:Eicosanoids; D005230:Fatty Acids, Nonesterified; D006025:Glycosaminoglycans; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D007371:Interferon-gamma; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2